Sections
| Title | Starting Page | Number of Pages |
|---|
| Table of Contents | 6 | 7 |
| List of Tables | 9 | 2 |
| List of Figures | 11 | 2 |
| Neurodegenerative Diseases Market to 2018: Introduction | 13 | 1 |
| Neurodegenerative Diseases Market to 2018: Global Market Overview | 14 | 5 |
| Revenue | 14 | 2 |
| Treatment Usage Pattern | 16 | 1 |
| Distribution by Market | 17 | 1 |
| Drivers and Restraints of the Neurodegenerative Diseases Market | 18 | 1 |
| Drivers | 18 | 1 |
| Growing and Aging Populations | 18 | 1 |
| Numerous Late-Stage Pipeline Molecules across all Indications | 18 | 1 |
| Restraints | 18 | 1 |
| Patent Expiries | 18 | 1 |
| Therapeutic Landscape | 19 | 109 |
| Market for Alzheimer s Disease | 19 | 1 |
| Introduction | 19 | 2 |
| Revenue and Forecasts | 21 | 2 |
| Treatment Usage Pattern | 23 | 1 |
| Geographical Landscape | 24 | 1 |
| US | 25 | 1 |
| Revenue and Forecasts | 25 | 1 |
| Annual Cost of Therapy | 26 | 1 |
| Treatment Usage Pattern | 27 | 1 |
| UK | 28 | 1 |
| Revenue and Forecasts | 28 | 1 |
| Annual Cost of Therapy | 29 | 1 |
| Treatment Usage Pattern | 30 | 1 |
| France | 31 | 1 |
| Revenue and Forecasts | 31 | 1 |
| Annual Cost of Therapy | 32 | 1 |
| Treatment Usage Pattern | 33 | 1 |
| Germany | 34 | 1 |
| Revenue and Forecasts | 34 | 1 |
| Annual Cost of Therapy | 35 | 1 |
| Treatment Usage Pattern | 36 | 1 |
| Italy | 37 | 1 |
| Revenue and Forecasts | 37 | 1 |
| Annual Cost of Therapy | 38 | 1 |
| Treatment Usage Pattern | 39 | 1 |
| Spain | 40 | 1 |
| Revenue and Forecasts | 40 | 1 |
| Annual Cost of Therapy | 41 | 1 |
| Treatment Usage Pattern | 42 | 1 |
| Japan | 43 | 1 |
| Revenue and Forecasts | 43 | 1 |
| Annual Cost of Therapy | 44 | 1 |
| Treatment Usage Pattern | 45 | 1 |
| Drivers and Restraints for the Alzheimer s Disease Market | 46 | 1 |
| Drivers | 46 | 1 |
| Promising Late-Stage Pipeline Candidates | 46 | 1 |
| Rising Prevalence of Alzheimer s Disease as the Population Ages | 46 | 1 |
| Restraints | 46 | 1 |
| Low Diagnosis Rates | 46 | 1 |
| Doubts over Phase III Pipeline Failures | 46 | 1 |
| Market for Parkinson s Disease | 47 | 1 |
| Introduction | 47 | 2 |
| Revenue and Forecasts | 49 | 1 |
| Treatment Usage Pattern | 50 | 1 |
| Geographical Landscape | 51 | 1 |
| US | 52 | 1 |
| Revenue and Forecasts | 52 | 1 |
| Annual Cost of Therapy | 53 | 1 |
| Treatment Usage Pattern | 54 | 1 |
| UK | 55 | 1 |
| Revenue and Forecasts | 55 | 1 |
| Annual Cost of Therapy | 56 | 1 |
| Treatment Usage Pattern | 57 | 1 |
| France | 58 | 1 |
| Revenue and Forecasts | 58 | 1 |
| Annual Cost of Therapy | 59 | 1 |
| Treatment Usage Pattern | 60 | 1 |
| Germany | 61 | 1 |
| Revenue and Forecasts | 61 | 1 |
| Annual Cost of Therapy | 62 | 1 |
| Treatment Usage Pattern | 63 | 1 |
| Italy | 64 | 1 |
| Revenue and Forecasts | 64 | 1 |
| Annual Cost of Therapy | 65 | 1 |
| Treatment Usage Pattern | 66 | 1 |
| Spain | 67 | 1 |
| Revenue and Forecasts | 67 | 1 |
| Annual Cost of Therapy | 68 | 1 |
| Treatment Usage Pattern | 69 | 1 |
| Japan | 70 | 1 |
| Revenue and Forecasts | 70 | 1 |
| Annual Cost of Therapy | 71 | 1 |
| Treatment Usage Pattern | 72 | 1 |
| Drivers and Restraints for the Parkinson s Disease Market | 73 | 1 |
| Drivers | 73 | 1 |
| Strong Late-Stage Pipeline | 73 | 1 |
| Growing and Aging Populations | 73 | 1 |
| Restraints | 73 | 1 |
| Looming Patent Cliff | 73 | 1 |
| Market for Amyotrophic Lateral Sclerosis | 74 | 1 |
| Introduction | 74 | 2 |
| Revenue and Forecasts | 76 | 1 |
| Treatment Usage Pattern | 77 | 1 |
| Geographical Landscape | 78 | 1 |
| US | 79 | 1 |
| Revenue and Forecasts | 79 | 1 |
| Annual Cost of Therapy | 80 | 1 |
| Treatment Usage Pattern | 81 | 1 |
| UK | 82 | 1 |
| Revenue and Forecasts | 82 | 1 |
| Annual Cost of Therapy | 83 | 1 |
| Treatment Usage Pattern | 84 | 1 |
| France | 85 | 1 |
| Revenue and Forecasts | 85 | 1 |
| Annual Cost of Therapy | 86 | 1 |
| Treatment Usage Pattern | 87 | 1 |
| Germany | 88 | 1 |
| Revenue and Forecasts | 88 | 1 |
| Annual Cost of Therapy | 89 | 1 |
| Treatment Usage Pattern | 90 | 1 |
| Italy | 91 | 1 |
| Revenue and Forecasts | 91 | 1 |
| Annual Cost of Therapy | 92 | 1 |
| Treatment Usage Pattern | 93 | 1 |
| Spain | 94 | 1 |
| Revenue and Forecasts | 94 | 1 |
| Annual Cost of Therapy | 95 | 1 |
| Treatment Usage Pattern | 96 | 1 |
| Japan | 97 | 1 |
| Revenue and Forecasts | 97 | 1 |
| Annual Cost of Therapy | 98 | 1 |
| Treatment Usage Pattern | 99 | 1 |
| Drivers and Restraints for the Amyotrophic Lateral Sclerosis Market | 100 | 1 |
| Drivers | 100 | 1 |
| Widespread Usage of Pharmacological Treatment | 100 | 1 |
| High Unmet Need | 100 | 1 |
| Restraints | 100 | 1 |
| Weak Pipeline | 100 | 1 |
| Lack of Treatment Options | 100 | 1 |
| Low Prevalence | 100 | 1 |
| Market for Huntington s Disease | 101 | 1 |
| Introduction | 101 | 2 |
| Revenue and Forecasts | 103 | 1 |
| Treatment Usage Pattern | 104 | 1 |
| Geographical Landscape | 105 | 1 |
| US | 106 | 1 |
| Revenue and Forecasts | 106 | 1 |
| Annual Cost of Therapy | 107 | 1 |
| Treatment Usage Pattern | 108 | 1 |
| UK | 109 | 1 |
| Revenue and Forecasts | 109 | 1 |
| Annual Cost of Therapy | 110 | 1 |
| Treatment Usage Pattern | 111 | 1 |
| France | 112 | 1 |
| Revenue and Forecasts | 112 | 1 |
| Annual Cost of Therapy | 113 | 1 |
| Treatment Usage Pattern | 114 | 1 |
| Germany | 115 | 1 |
| Revenue and Forecasts | 115 | 1 |
| Annual Cost of Therapy | 116 | 1 |
| Treatment Usage Pattern | 117 | 1 |
| Italy | 118 | 1 |
| Revenue and Forecasts | 118 | 1 |
| Annual Cost of Therapy | 119 | 1 |
| Treatment Usage Pattern | 120 | 1 |
| Spain | 121 | 1 |
| Revenue and Forecasts | 121 | 1 |
| Annual Cost of Therapy | 122 | 1 |
| Treatment Usage Pattern | 123 | 1 |
| Japan | 124 | 1 |
| Revenue and Forecasts | 124 | 1 |
| Annual Cost of Therapy | 125 | 1 |
| Treatment Usage Pattern | 126 | 1 |
| Drivers and Restraints for the Huntington s Disease Market | 127 | 1 |
| Drivers | 127 | 1 |
| Strong Late-Stage Pipeline Candidates | 127 | 1 |
| High Unmet Need | 127 | 1 |
| Restraints | 127 | 1 |
| Low Prevalence | 127 | 1 |
| Small Pipeline | 127 | 1 |
| Neurodegenerative Diseases Market: Pipeline Analysis | 128 | 30 |
| Introduction | 128 | 1 |
| Summary of the Current Neurodegenerative Diseases R&D Pipeline | 129 | 1 |
| Alzheimer's Disease | 129 | 1 |
| Introduction | 129 | 13 |
| Amyotrophic Lateral Sclerosis | 142 | 1 |
| Introduction | 142 | 5 |
| Parkinson s Disease | 147 | 1 |
| Introduction | 147 | 8 |
| Huntington s Disease | 155 | 1 |
| Introduction | 155 | 3 |
| Neurodegenerative Diseases Market: Deals and Strategic Consolidations | 158 | 18 |
| Merger and Acquisition Deals | 158 | 2 |
| Sanofi-Synthelabo Merges with Aventis | 160 | 1 |
| Bayer Acquires Schering | 160 | 1 |
| Takeda Pharma Completes Acquisition of Nycomed International for $13,681m | 160 | 1 |
| Teva Pharma Acquires Ivax | 160 | 1 |
| Abbott Labs Acquires Solvay Pharma | 160 | 1 |
| Teva Completes Acquisition of Cephalon for $6.8 billion | 160 | 1 |
| UCB Acquires 87.62% Stake in Schwarz Pharma | 161 | 1 |
| Biovail Acquires Valeant Pharma | 161 | 1 |
| Dainippon Sumitomo Pharma Completes Acquisition of Sepracor for $2.6 Billion | 161 | 1 |
| Merck Acquires Banyu Pharma | 161 | 1 |
| Amgen Completes Acquisition of Micromet for $1.2 Billion | 161 | 1 |
| Bayer Acquires Minority Stake in Bayer Schering Pharma | 161 | 1 |
| Daiichi Sankyo Completes Acquisition of Plexxikon | 162 | 1 |
| Lundbeck Acquires Ovation Pharma | 162 | 1 |
| Eli Lilly and Company Acquires Avid RadioPharma | 162 | 1 |
| Abbott Labs Completes Acquisition of Facet Biotech | 162 | 1 |
| Biogen Idec Acquires Fumapharm | 162 | 1 |
| Upsher-Smith Completes Acquisition of Remaining 84% Stake in Proximagen for up to $555m | 163 | 1 |
| Sun Pharma Acquires Controlling Stake in Taro Pharma | 163 | 1 |
| Pfizer Acquires Rinat Neuroscience | 163 | 1 |
| Cubist Pharma Completes Acquisition of Adolor for $415m | 163 | 1 |
| Biogen Idec Acquires Panima Pharma | 164 | 1 |
| Teva Pharma Acquires CoGenesys from New Enterprise, Orbimed and Red Abbey | 164 | 1 |
| Fujifilm Holdings Acquires 66% Stake in Toyama Chemical | 164 | 1 |
| MGI PHARMA Acquires Guilford Pharma | 164 | 1 |
| H. Lundbeck Acquires LifeHealth | 164 | 1 |
| Endo Pharma Completes Acquisition of Penwest Pharma | 165 | 1 |
| EPIX Pharma Acquires Predix Pharma | 165 | 1 |
| Biogen Idec Acquires Syntonix Pharmaceuticals | 165 | 1 |
| Biotie Therapies Acquires Synosia Therapeutics | 165 | 1 |
| Licensing Agreements | 166 | 1 |
| Cephalon Enters into a Licensing Agreement with Mesoblast for Regenerative Medicine | 167 | 1 |
| Idera Pharma Enters into a Licensing Agreement with Merck | 167 | 1 |
| Astellas Pharma Enters into Licensing Agreement with CoMentis for Beta-Secretase Inhibitors | 167 | 1 |
| Synosia Therapeutics Enters into Licensing Agreement with UCB for SYN-115 and SYN-118 | 167 | 1 |
| GlaxoSmithKline Signs an Agreement with AFFiRiS | 168 | 1 |
| Biogen Enters into an Agreement with Acorda Therapeutics | 168 | 1 |
| BioMS Medical Enters into Licensing Agreement with Eli Lilly | 168 | 1 |
| AC Immune Enters into Licensing Agreement with Genentech for Anti-Tau Antibodies | 168 | 1 |
| Biovail Enters into Licensing Agreement with Acadia Pharmaceuticals | 168 | 1 |
| Biogen Idec Enters into Licensing Agreement with Knopp Neurosciences for KNS-760704 | 169 | 1 |
| AstraZeneca Enters into Licensing Agreement with Targacept | 169 | 1 |
| AC Immune Enters into Licensing Agreement with Genentech | 169 | 1 |
| Proximagen Enters into Licensing Agreement with Upsher-Smith Labs | 169 | 1 |
| Merck Serono Enters into Licensing Agreement with Apitope Technology | 170 | 1 |
| Serono Enters into Licensing Agreement with Newron Pharma for Safinamide | 170 | 1 |
| Shire Exercises Option to License Adenosine A2A from Heptares Therapeutics | 170 | 1 |
| GlaxoSmithKline Enters into Licensing Agreement with Impax Pharma for IPX066 | 170 | 1 |
| Santhera Pharmaceuticals Enters into Licensing Agreement with Ipsen for Fipamezole | 171 | 1 |
| Domain Therapeutics Enters into Licensing Agreement with Merck Serono | 171 | 1 |
| Addex Pharma Enters into Collaboration and Licensing Agreement with Merck &Co | 171 | 1 |
| Curis Enters into Licensing Agreement with Wyeth Pharma | 171 | 1 |
| Pfizer Enters into a License and Collaboration Agreement with Transtech Pharma | 171 | 1 |
| Antisense Therapeutics Enters into Licensing Agreement with Teva Pharma | 172 | 1 |
| Biogen Idec Enters into Licensing Agreement with Vernalis | 172 | 1 |
| Co-Development Deals | 173 | 1 |
| GlaxoSmithKline Signs an Agreement with Targacept | 174 | 1 |
| GlaxoSmithKline Enters into an Agreement with EPIX Pharma | 174 | 1 |
| Evotec Enters into Co-Development Agreement with Roche | 174 | 1 |
| Pfizer Enters into Co-Development Agreement with Medivation for Dimebon | 174 | 1 |
| Alectos Therapeutics Enters into Research Collaboration with Merck &Co | 174 | 1 |
| Targacept Expands its Collaboration Agreement with AstraZeneca | 175 | 1 |
